QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Forecast, Price & News

$0.38
+0.01 (+2.69%)
(As of 09/27/2023 ET)
Compare
Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.54
52-Week Range
$0.38
$2.61
Volume
930,099 shs
Average Volume
5.82 million shs
Market Capitalization
$102.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Inovio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
424.0% Upside
$2.00 Price Target
Short Interest
Healthy
5.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.52
Upright™ Environmental Score
News Sentiment
0.81mentions of Inovio Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.52) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

377th out of 976 stocks

Surgical & Medical Instruments Industry

46th out of 99 stocks


INO stock logo

About Inovio Pharmaceuticals (NASDAQ:INO) Stock

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Price History

INO Stock News Headlines

Something is Coming for America's Top Stock
This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.
Inovio Pharmaceuticals (NASDAQ:INO) Now Covered by StockNews.com
Something is Coming for America's Top Stock
This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.
Inovio's CEO Defends Swine Flu Drug (Part 2)
Inovio : EU Grants Orphan Drug Designation For INO-3107
See More Headlines
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Company Calendar

Last Earnings
8/09/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
135
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+433.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-279,820,000.00
Net Margins
-1,750.84%
Pretax Margin
-1,750.84%

Debt

Sales & Book Value

Annual Sales
$10.26 million
Book Value
$0.89 per share

Miscellaneous

Free Float
262,714,000
Market Cap
$100.58 million
Optionable
Optionable
Beta
0.97

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Jacqueline E. Shea Ph.D. (Age 57)
    CEO, Pres & Director
    Comp: $1.08M
  • Mr. Peter D. KiesMr. Peter D. Kies (Age 60)
    Chief Financial Officer
    Comp: $688.72k
  • Dr. Laurent M. Humeau Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $673.59k
  • Thomas Hong
    Mang. of Investor Relations
  • Mr. Robert L. Crotty J.D. (Age 49)
    Gen. Counsel & Chief Compliance Officer
  • Mr. E. J. Brandreth MBA
    Sr. VP of Quality Assurance
  • Dr. Jeffrey Skolnik
    Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr.
    Sr. VP of Biological Manufacturing & Clinical Supply Management
  • Mr. Stephen Kemmerrer M.B.A.
    P.E., Sr. VP of Engineering Devel.
  • Mr. Shawn D. Bridy M.A.
    M.B.A., MA, MBA, Sr. VP of Bus. Devel.













INO Stock - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" INO shares.
View INO analyst ratings
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their INO share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 433.0% from the stock's current price.
View analysts price targets for INO
or view top-rated stocks among Wall Street analysts.

How have INO shares performed in 2023?

Inovio Pharmaceuticals' stock was trading at $1.56 at the start of the year. Since then, INO shares have decreased by 75.9% and is now trading at $0.3752.
View the best growth stocks for 2023 here
.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,630,000 shares, a decline of 6.4% from the August 31st total of 16,700,000 shares. Based on an average daily trading volume, of 4,300,000 shares, the short-interest ratio is currently 3.6 days.
View Inovio Pharmaceuticals' Short Interest
.

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our INO earnings forecast
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analysts' expectations of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 78.56% and a negative net margin of 1,750.84%. During the same period in the previous year, the company earned ($0.46) EPS.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.32%), Renaissance Technologies LLC (2.07%), Geode Capital Management LLC (1.09%), Charles Schwab Investment Management Inc. (0.48%), State Street Corp (0.33%) and Y Intercept Hong Kong Ltd (0.24%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $0.38.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $100.58 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

The company employs 135 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -